Body fluid biomarkers in multiple sclerosis by Comabella, Manuel, Dr, Montalban, Xavier, Prof

Get full text

MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines by Filippi, Massimo, Prof, Rocca, Maria A, MD, Ciccarelli, Olga, Prof, De Stefano, Nicola, MD, Evangelou, Nikos, PhD, Kappos, Ludwig, Prof, Rovira, Alex, MD, Sastre-Garriga, Jaume, MD, Tintorè, Mar, MD, Frederiksen, Jette L, Prof, Gasperini, Claudio, MD, Palace, Jacqueline, MD, Reich, Daniel S, MD, Banwell, Brenda, Prof, Montalban, Xavier, Prof, Barkhof, Frederik, Prof

Get full text

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial by Lublin, Fred, Prof, Miller, David H, Prof, Freedman, Mark S, Prof, Cree, Bruce A C, Prof, Wolinsky, Jerry S, Prof, Weiner, Howard, Prof, Lubetzki, Catherine, Prof, Hartung, Hans-Peter, Prof, Montalban, Xavier, Prof, Uitdehaag, Bernard M J, Prof, Merschhemke, Martin, MD, Li, Bingbing, PhD, Putzki, Norman, MD, Liu, Fonda C, PharmD, Häring, Dieter A, PhD, Kappos, Ludwig, Prof

Get full text

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial by Gold, Ralf, Prof, Giovannoni, Gavin, Prof, Selmaj, Krzysztof, Prof, Havrdova, Eva, Prof, Montalban, Xavier, Prof, Radue, Ernst-Wilhelm, Prof, Stefoski, Dusan, MD, Robinson, Randy, PhD, Riester, Katherine, MPH, Rana, Jitesh, MD, Elkins, Jacob, MD, O'Neill, Gilmore, MRCPI

Get full text

Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study by Selmaj, Krzysztof, Prof, Li, David KB, Prof, Hartung, Hans-Peter, Prof, Hemmer, Bernhard, Prof, Kappos, Ludwig, Prof, Freedman, Mark S, Prof, Stüve, Olaf, MD, Rieckmann, Peter, Prof, Montalban, Xavier, Prof, Ziemssen, Tjalf, MD, Auberson, Lixin Zhang, MD, Pohlmann, Harald, MSc, Mercier, Francois, PhD, Dahlke, Frank, MD, Wallström, Erik, MD

Get full text

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial by Giovannoni, Gavin, Prof, Gold, Ralf, Prof, Selmaj, Krzysztof, Prof, Havrdova, Eva, Prof, Montalban, Xavier, Prof, Radue, Ernst-Wilhelm, Prof, Stefoski, Dusan, MD, McNeill, Manjit, MSc, Amaravadi, Lakshmi, PhD, Sweetser, Marianne, MD, Elkins, Jacob, MD, O'Neill, Gilmore, MRCPI

Get full text

Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial by Miller, David H, Prof, Weber, Thomas, Prof, Grove, Richard, MSc, Wardell, Claire, PhD, Horrigan, Joseph, MD, Graff, Ole, MD, Atkinson, Gillian, PhD, Dua, Pinky, PhD, Yousry, Tarek, Prof, MacManus, David, MSc, Montalban, Xavier, Prof

Get full text

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT... by Kappos, Ludwig, Prof, Freedman, Mark S, Prof, Polman, Chris H, Prof, Edan, Gilles, Prof, Hartung, Hans-Peter, Prof, Miller, David H, Prof, Montalbán, Xavier, Prof, Barkhof, Frederik, Prof, Radü, Ernst-Wilhelm, Prof, Bauer, Lars, MD, Dahms, Susanne, PhD, Lanius, Vivian, PhD, Pohl, Christoph, MD, Sandbrink, Rupert, MD

Get full text

Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects by Cohen, Jeffrey A, Prof, Reingold, Stephen C, PhD, Polman, Chris H, Prof, Wolinsky, Jerry S, Prof

Get full text